Know Cancer

or
forgot password

Structural Imaging and Cognitive Functions in Adult Stem Cell Transplant Recipients Treated With Chemotherapy Alone or in Combination With Radiotherapy


N/A
18 Years
70 Years
Open (Enrolling)
Both
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Undifferentiated Leukemia, Biphenotypic Leukemia, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma

Thank you

Trial Information

Structural Imaging and Cognitive Functions in Adult Stem Cell Transplant Recipients Treated With Chemotherapy Alone or in Combination With Radiotherapy


Inclusion Criteria:



- Diagnosed with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL),
acute undifferentiated or biphenotypic leukemia, myelodysplastic syndrome (MDS),
Hodgkin's lymphoma, (HL) or non-Hodgkin's lymphoma (NHL), and in complete remission
at the time of enrollment

- Are scheduled to undergo conditioning treatment with (1) total body radiation (TBI)
and chemotherapy or (2) chemotherapy alone prior to receiving a myeloablative
allogeneic HSCT

- Between 18 and 70 years of age.

- Are English speaking.

- Have capacity to give consent.

Healthy Control

Inclusion Criteria:



- Have no diagnosis of cancer except basal cell carcinoma

- Between 18 and 70 years of age.

- Are English speaking.

- Have capacity to give consent

Exclusion Criteria:

- Patients with signs and/or symptoms of central nervous system disease as determined
by their physician or by a brain MRI, either at the time of enrollment or during the
study period.

- With disease progression at the time of enrollment or during the study period

- With self-reported Axis I psychiatric disorder (DSM-IV), major affective disorder
(untreated), bipolar disorder, schizophrenia

- With a history of a neurological disorder, neurodegenerative disease, or traumatic
brain injury with loss of consciousness

- With standard contraindications to MRI examinations

Healthy Control Exclusion Criteria:

- Exposure to chemotherapy or radiation therapy for any medical condition

- With self-reported Axis I psychiatric disorder (DSM-IV), major affective disorder
(untreated), bipolar disorder, schizophrenia

- With a history of neurological disorders, neurodegenerative disease, or traumatic
brain injury with loss of consciousness

- With standard contraindications to MRI examinations

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

assess changes in hippocampal volume & white matter integrity prospectively in adult ca pts who get treatment w/i chemotherapy alone or in combination with total body irradiation (TBI) before undergoing hematopoietic stem cell transplantation.

Outcome Time Frame:

conclusion of the study

Safety Issue:

No

Principal Investigator

Denise Correa, PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Memorial Sloan-Kettering Cancer Center

Authority:

United States: Institutional Review Board

Study ID:

06-162

NCT ID:

NCT00606216

Start Date:

January 2007

Completion Date:

December 2013

Related Keywords:

  • Acute Myeloid Leukemia
  • Acute Lymphoblastic Leukemia
  • Acute Undifferentiated Leukemia
  • Biphenotypic Leukemia
  • Myelodysplastic Syndrome
  • Non-Hodgkin's Lymphoma
  • MRI
  • Leukemia
  • Leukemia, Lymphoid
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • Leukemia, Myeloid, Acute
  • Leukemia, Myeloid
  • Lymphoma
  • Lymphoma, Non-Hodgkin
  • Myelodysplastic Syndromes
  • Preleukemia

Name

Location

Memorial Sloan Kettering Cancer CenterNew York, New York  10021
Weill Cornell Medical CenterNew York, New York  10021